These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 36614045)
1. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report. Chen ZW; Lin G; Shih HJ; Wu CE Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045 [TBL] [Abstract][Full Text] [Related]
2. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596 [TBL] [Abstract][Full Text] [Related]
3. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908 [TBL] [